The population can be divided into four groups, or "oncodemes," depending on the relative contributionsof environment and genetics to their risk of cancer. These oncodemes are: 1) background (random mutations in normal people); 2) environmental (environmental carcinogens acting on normal people); 3) environmental/genetic (environmental carcinogens acting on genetic susceptibility); and 4) genetic, with genetic susceptibilitybeing more important than environmental exposure. Most cancer probably occurs in oncodemes 2 and 3. However, the contribution that genetic susceptibilityto cancer makes to the total cancer burden is unknown. Genetic susceptibilitymay be important in occupational settings,where exposure to carcinogens is presumed to be restricted to concentrations believed to confer "acceptable" risks.This approach takes no account of indMdual susceptibility. The range over which metabolic polymorphisms exert their effects suggests that differences in pharmacogenetics between individuals may be important in occupational carcinogenesis. If this range were extrapolated to risk of human disease, at a given exposure one person might be 10-200 times more sensitive than another. Several metabolic polymorphisms have been linked to susceptibility to cancer. For some of these polymorphisms,genes have been cloned and genotypic tests based on use of the polymerase chain reaction have been developed. Limiteddata suggest that the effects of these polymorphisms on human cancer are complex.
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The genotypic testing of individuals occupationally exposed to carcinogens may providefirmer informationon the relative contributionsof nature and nurture on chemically induced cancer. The use to which such information is put demands wide debate.
IndexIng Terms: genetic oncodemes/metabolic polymorphisms
With rare exceptions, the development of cancer in an individual depends on a complex interplay between natore and nurture
(genetics and environment).
It is therefore impossible, at present, to determine the precise contribution that individual susceptibility makes to risk of cancer in a given population.
The problem has been addressed by Knudson (1 
Multistep Carcinogenesis and Cancer Genes
It is generally accepted that the malignant phenotype develops as a result of an accumulation of mutations in genes that play a critical role in the control of cell division, growth, and differentiation.
Epigenetic phenomena, such as hypomethylation of DNA, also participate in the process (4) (5) (6) . This stepwise accretion of mutations is accompanied by a series of histopathological changes in which normal epithelium progresses to benign neoplasia (which in some people is reversible); the neoplasia in turn becomes dysplastic, invasive, and ultimately metastatic. The most well-documented example of this process is colorectal cancer (7) (Fig. 1) Oth.r aft.rattons As their name suggests, tumor-suppressor genes inhibit cell proliferation that would otherwise lead to neoplasia. Tumor-suppressor genes are inactivated by point mutation, chromosomal loss or deletion, somatic recombination, or gene conversion (5, 6). The mechanisms by which tumor-suppressor genes function are largely unknown. However, recent studies suggest that p53, a tumor-suppressor gene that is mutated in more than half of the human cancers seen in Western countries, is involved in the control of apoptosis (programmed cell death) in response to agents such as ionizing radiation and chemical mutagens.
A dead cell cannot pass on a mutation.
It is suggested that a cell that contains a mutant allele of p53 is more likely to survive a genotoxic insult than is a normal cell, and is therefore more likely to survive a mutation in the other p53 allele by virtue of its reduced propensity to undergo apoptosis. Mutation in one p53 allele and loss of the second allele is frequently seen in cancer cells ( it causes gross distortion of the DNA structure. Adduct formation can lead to base substitution, deletion, and addition, and, therefore, to point mutation.
Metabolic ActIvation of Carcinogens
Many carcinogens only bind to DNA after undergoing metabolism to more reactive species. These are not electrophilic per se, but are converted to electrophiles by eukaryotic cellular enzyme systems. This process of metabolic activation is a normal biochemical activity of mammals, allowing detoxification and elimination of potentially toxic substances that are generated by normal metabolism, are ingested in the diet, or enter the body in the form of drugs, occupational chemicals, or environmental contaminants.
Enzymes with these functions fall into two main classes: phase I and phase 11(23, 24) .
Most phase I enzymes are members of the cytochrome P450 superfamily of enzymes-"monooxygenases"-that carry out oxidative metabolism by inserting one atom of oxygen into a relatively inert and usually nonpolar substrate. Cytochrome
P450s catalyze the biosynthesis and degradation of many normal biochemical substrates, including steroids, fatty acids, prostaglandins, leukotrienes, biogenic amines, and plant metabolites.
Phase 
Inherited SusceptibIlIty to Cancer
Given that somatic mutation, however provoked, initiates cancer, there will always be a background incidence for any given cancer because, by its nature, spontaneous mutation is impossible to prevent and is indeed the driving force of evolution. However, evidence suggests that the background incidence is a small fraction of the total (27) and that most cancer occurs in people who adopt a lifestyle with a particular carcinogenic risk (e.g., smoking; overnutrition) and (or) have a genetic susceptibffity to cancer-oncodemes 2 and 3. Genetic susceptibility to cancer can take several forms. In the most extreme cases a family will exhibit Mendelian inheritance of a mutant cancer gene that predisposes that person to cancer at one or more sites, the predisposition being carried on a single autosomal dominant gene. FAP is such a trait. An affected individual develops hundreds or thousands of colonic polyps during adolescence. Some of these progress to malignancy, and the patient will inevitably develop colon cancer by the third or fourth decade unless a prophylactic colectomy is per- 
Metabolic Polymorphisms and Cancer
The extent to which the inherited dispositions to cancer discussed thus far contribute to the total burden of human cancer is unknown, but it is usually estimated to be between 1% and 5%, although this may be a serious underestimation (2). Accurate estimates of the fraction of human cancer that can be ascribed to genetic susceptibility cannot be made until we know far more about the role of metabolic polymorphisms in determining susceptibility to cancer. A polymorphic gene exists, in a given population, as two or more alleles at the same locus. The gene product of each allele will differ (sometimes by only one amino acid), and the differences are detectable at the phenotypic level by variations, e.g., in electrophoretic mobility or enzyme activity. There are numerous examples of metabolic polymorphisms in the human population, their effects being manifest by large differences in response to the same drug by different individuals (24). Four such polymorphisms have been linked to susceptibifity to cancer (Table 1) 
lators, 2-17-fold).
Because exposure to arylainines (e.g., in the rubber industry) is linked with bladder cancer, and because N-acetyltransferase conjugates and detoxifies arylainines such as benzidine and 2-naphthylamine, it is plausible that slow acetylators should be at higher risk of bladder cancer than fast acetylators. However, a recent study based on both genotyping and phenotyping, conducted on a group of Chinese workers cccupationally exposed to benzidine, failed to find any excess risk of cancer in individuals with slow rates of acetylation.
Indeed, a protective effect of the slow-acetylation allele was claimed (30) . Although this study showed that phenotyping and genotyping gave closely similar results, it must be borne in mind that most studies of metabolic polymorphisms and cancer published to date have been based on the use of phenotypic markers (5). The ratio of a specific urinary metabolite of an orally administered drug to its unchanged form is a typical method of phenotyping. Phenotypic testing is subject to a variety of confounding factors (e.g., age, sex, diet, smoking, and the possible effects of the disease being studied) that may interfere with its conduct or interpretation.
However, genes for four of the polymorphisms associated with human cancer have been cloned and are now being used in simple, noninvasive genotypic tests in which, e.g., DNA from white blood cells is subjected to the polymerase chain reaction to amplify the gene of interest (30, 31 
